Based on the cost-benefit analysis performed by FDA , the rule will impose an unfunded mandate on the private sector of over $ 100 million annually and therefore the rule is subject to the requirements of the Act .
The rule imposing an unfunded mandate on the private sector is based on the FDA 's cost-benefit analysis .